Viewing Gene With Clinical Trials Data

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Report Bug Request Feature
Gene Data From HGNC: https://www.genenames.org/download/statistics-and-files/
Symbol: NTRK1
Name: neurotrophic receptor tyrosine kinase 1
Location: 01q23.1
Locus Group: protein-coding gene
Gene Type: Protein Coding
Locus Type: gene with protein product
ID+ Clinical Trials CompTox DrugMatrix Conditions Design Enrollment Locations Outcomes
Clinical Trials Data: https://classic.clinicaltrials.gov/api/gui/ref/download_all

Clinical Studies

NCT Number Status Brief Title View
NCT03093116 A Study of Repotrectinib TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK ROS1 or NTRK1-3 Rearrangements View
NCT02219711 Phase 11b Study of MGCD516 in Patients With Advanced Cancer View
NCT02650401 Study Of Entrectinib Rxdx-101 in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors AndOr Who Have No Satisfactory Treatment Options View
NCT02568267 Basket Study of Entrectinib RXDX-101 for the Treatment of Patients With Solid Tumors Harboring NTRK 123 Trk ABC ROS1 or ALK Gene Rearrangements Fusions View
NCT02920996 Merestinib In Non-Small Cell Lung Cancer And Solid Tumors View
NCT03206931 Expanded Access to Provide Selitrectinib for the Treatment of Cancers With a NTRK Gene Fusion View
NCT03375437 RNASARC - Molecular Screening Program of Soft Tissue Sarcomas With Complex Genomic Profile to Detect NTRK123 ROS1 or ALK Gene Fusions View
NCT04671849 An Open Label Multi-center Phase I Clinical Study to Evaluate the Safety Effectiveness and Pharmacokinetic Characteristics of SIM1803-1A in Patients With Locally AdvancedMetastatic Solid Tumors With NTRK ROS1 or ALK Gene Fusion Mutations View
NCT04094610 A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK ROS1 OR NTRK1-3 Alterations View
NCT03025360 Expanded Access to Provide Larotrectinib for the Treatment of Cancers With a NTRK Gene Fusion View
NCT04557813 Registry for Molecular Testing Treatment and Outcome of Patients With Solid Tumors Harboring a NTRK Gene Fusion View
NCT02576431 A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors View
NCT05769075 A Study of TY-2136b in Patients With Advanced Solid Tumors Harboring ALK ROS1 or NTRK1-3 Alterations View
NCT05828303 A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin Digoxin and Rosuvastatin in Patients With Advanced Solid Tumors View
NCT02097810 Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1 NTRK2 NTRK3 ROS1 or ALK Molecular Alterations View
NCT02122913 A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer View
NCT03182257 Study of ONO-7579 in Patients With Advanced Solid Tumors NTRK Gene Fusion Positive Advanced Solid Tumors View
NCT02637687 A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children View
NCT03215511 A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer View
NCT03556228 Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma View